Antibody reactivity against EBNA1 and GlialCAM differentiates multiple sclerosis patients from healthy controls.

Proc Natl Acad Sci U S A · 2025 · PMC11929495 · PMID 40063790

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Notably, a prior study had described highly significant differences in anti-GlialCAM AA370-389 IgG levels between MS patients and healthy controls in a cohort of 540 individuals, with P-values below 0.0001 ( 29 ). 100% of MS patients in this study had relatively high anti-GlialCAM antibody levels, and these were distinct from 60% of healthy controls whose antibody reactivities were approximately twofold lower.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.